<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002883" GROUP_ID="AIRWAYS" ID="621100051111214510" MERGED_FROM="" MODIFIED="2010-11-05 18:51:49 +0100" MODIFIED_BY="Emma Welsh" NOTES="&lt;p&gt;Exported from Review Manager 4.2.1&lt;/p&gt;&lt;p&gt;Liz Arnold read, revised and approved search strategy 261004&lt;br&gt;-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 17:51:14 +0000" NOTES_MODIFIED_BY="Emma J Welsh" REVIEW_NO="DOX-ILD" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2010-11-05 18:51:49 +0100" MODIFIED_BY="Emma Welsh">
<TITLE>Domiciliary oxygen for interstitial lung disease</TITLE>
<CONTACT MODIFIED="2010-11-05 18:51:49 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="4557" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Alan</FIRST_NAME><LAST_NAME>Crockett</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>alan.crockett@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Primary Care Respiratory Unit, Discipline of General Practice</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><CITY>Adelaide</CITY><ZIP>5005</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>618 8303 7504</PHONE_1><PHONE_2>618 8303 3561</PHONE_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-11-05 18:51:49 +0100" MODIFIED_BY="Emma Welsh"><PERSON ID="4557" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Alan</FIRST_NAME><LAST_NAME>Crockett</LAST_NAME><POSITION>Associate Professor</POSITION><EMAIL_1>alan.crockett@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Primary Care Respiratory Unit, Discipline of General Practice</DEPARTMENT><ORGANISATION>The University of Adelaide</ORGANISATION><CITY>Adelaide</CITY><ZIP>5005</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>618 8303 7504</PHONE_1><PHONE_2>618 8303 3561</PHONE_2></ADDRESS></PERSON><PERSON ID="12402" ROLE="AUTHOR"><PREFIX>Mrs</PREFIX><FIRST_NAME>Josephine</FIRST_NAME><MIDDLE_INITIALS>M</MIDDLE_INITIALS><LAST_NAME>Cranston</LAST_NAME><POSITION>Affiliate Fellow</POSITION><EMAIL_1>josephine.cranston@adelaide.edu.au</EMAIL_1><ADDRESS><DEPARTMENT>Discipline of General Practice</DEPARTMENT><ORGANISATION>School of Population Health and Clinical Practice</ORGANISATION><ADDRESS_1>University of Adelaide</ADDRESS_1><CITY>Adelaide</CITY><ZIP>5005</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>+61 8 8278 6621</PHONE_1><FAX_1>+61 8 8303 3511</FAX_1></ADDRESS></PERSON><PERSON ID="12376" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Nic</FIRST_NAME><LAST_NAME>Antic</LAST_NAME><POSITION>Registrar</POSITION><ADDRESS><DEPARTMENT>Respiratory Unit</DEPARTMENT><ORGANISATION>Flinders Medical Centre</ORGANISATION><ADDRESS_1>Bedford Park</ADDRESS_1><CITY>Adelaide</CITY><ZIP>5042</ZIP><REGION>South Australia</REGION><COUNTRY CODE="AU">Australia</COUNTRY><PHONE_1>618 8204 4033</PHONE_1><PHONE_2>618 8204 4929</PHONE_2><FAX_1>618 8204 5632</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-11-05 17:47:03 +0000" MODIFIED_BY="Emma J Welsh" NOTES="&lt;p&gt;New studies sought but none found: 18/10/07&lt;/p&gt;" NOTES_MODIFIED="2010-11-05 17:47:03 +0000" NOTES_MODIFIED_BY="Emma J Welsh">
<UP_TO_DATE>
<DATE DAY="28" MONTH="10" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="10" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="10" YEAR="2012"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2001"/>
</DATES>
<WHATS_NEW MODIFIED="2010-11-04 18:52:58 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-04 18:52:58 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="28" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>Literature search run; no new studies found. Minor copy edits made.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-11-04 18:51:44 +0000" MODIFIED_BY="Emma J Welsh">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-11-04 18:51:44 +0000" MODIFIED_BY="Emma J Welsh">
<DATE DAY="28" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Literature search re-run; no new studies found</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-10-28 08:36:11 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="24" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Literature search re-run; no new studies were identified. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-27 09:12:07 +0000" MODIFIED_BY="Toby J Lasserson">
<DATE DAY="23" MONTH="7" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="22" MONTH="5" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>NHS Research and Development</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-11-05 17:51:14 +0000" MODIFIED_BY="Emma J Welsh">
<SUMMARY MODIFIED="2008-07-23 13:27:09 +0100" MODIFIED_BY="Toby J Lasserson">
<TITLE MODIFIED="2008-07-23 13:27:09 +0100" MODIFIED_BY="Toby J Lasserson">Domiciliary oxygen for interstitial lung disease</TITLE>
<SUMMARY_BODY>
<P>Oxygen therapy is used to treat patients with interstitial lung disease (ILD) with low arterial blood oxygen levels. This review evaluated the effect of domiciliary long-term oxygen therapy on survival and quality of life in patients with ILD. Only one randomized controlled trial was identified. This unpublished study reported that long-term oxygen therapy did not improve survival compared with no oxygen therapy in patients with ILD. No data on quality of life was available.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-11-05 11:34:09 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Retrospective survival data have suggested poor effectiveness of oxygen therapy in patients with interstitial lung disease (ILD). </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the effect of domiciliary oxygen therapy on survival and quality of life in patients with a diagnosis of ILD and hypoxaemia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-05 11:34:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomized Controlled Trials (RCTs) were identified from searches of the Airways Group Specialised Register, CENTRAL, MEDLINE and EMBASE. Searches were current as of October 2010. No language restrictions were applied.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Any randomized controlled trial (RCT) in adult patients with hypoxaemia and ILD that compared long term domiciliary or home oxygen therapy with a control group. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-10-28 08:37:10 +0000" MODIFIED_BY="Toby J Lasserson">
<P>Studies were assessed by two authors. Data were entered into Review Manager 5 and analysed. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-11-04 18:52:50 +0000" MODIFIED_BY="Emma J Welsh">
<P>Only one trial met the eligibility criteria of the review. Mortality for both the oxygen treated and control groups was approximately 91% after three years (Peto odds ratio 0.99, 95% confidence intervals 0.16 to 6.26). The effect of oxygen therapy on quality of life and physiological parameters was not reported.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The assumption that home oxygen therapy has a beneficial survival effect in patients with ILD has not been demonstrated in the single RCT identified.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-11-05 17:51:14 +0000" MODIFIED_BY="Emma J Welsh">
<BACKGROUND>
<P>Diffuse interstitial lung disease (ILD) refers to a heterogeneous group of acute or chronic progressive lung disorders with varying degrees of pulmonary inflammation and fibrosis. The aetiology of ILD is often unknown. The spectrum of patient diagnoses includes idiopathic pulmonary fibrosis, ILD with collagen vascular disease, granulomatous ILD, ILD caused through drug reaction or particle deposition, lymphangioleiomyomatosis, bronchocentric granulomatosis, and bronchiolitis obliterans with organizing pneumonia (<LINK REF="REF-Reynolds-1998" TYPE="REFERENCE">Reynolds 1998</LINK>). Patients with ILD often develop chronic hypoxaemia which is related to the progression of their underlying condition and has been treated with long-term home oxygen supplementation. Retrospective survival data have suggested poor effectiveness of oxygen therapy in ILD patients (<LINK REF="REF-Crockett-1991" TYPE="REFERENCE">Crockett 1991</LINK>). <BR/> </P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this review was to determine the effect of long-term domiciliary oxygen therapy on survival and quality of life in patients with a diagnosis of ILD and hypoxaemia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-11-05 17:51:14 +0000" MODIFIED_BY="Emma J Welsh">
<SELECTION_CRITERIA MODIFIED="2010-11-04 18:55:26 +0000" MODIFIED_BY="Emma J Welsh">
<CRIT_STUDIES>
<P>Any randomized controlled trial (RCT) in adult patients with hypoxaemia and ILD that compared long-term domiciliary or home oxygen therapy with a control group. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults with ILD, who received home oxygen therapy in the community. </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>The intervention in the active treatment group covered all forms of long-term domiciliary oxygen therapy including provision of home oxygen by cylinders, concentrators or liquid oxygen therapy. In the control group, the intervention was to be either placebo air by the same method of delivery or no specific intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-11-04 18:55:26 +0000" MODIFIED_BY="Emma J Welsh">
<P>The outcomes determined in advance for this review were:</P>
<OL>
<LI>Survival</LI>
<LI>Health related quality of life as measured by a validated instrument</LI>
<LI>Improvement in physiological parameters</LI>
</OL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-05 17:51:14 +0000" MODIFIED_BY="Emma J Welsh">
<ELECTRONIC_SEARCHES MODIFIED="2010-11-05 17:51:14 +0000" MODIFIED_BY="Emma J Welsh">
<P>Trials were identified from the following sources:</P>
<UL>
<LI>Airways Group Specialised Register (all years to October 2010)</LI>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 4, 2010)</LI>
<LI>MEDLINE (1950-October 2010)</LI>
<LI>EMBASE (1980-October 2010)</LI>
</UL>
<P>No language restrictions were applied. The search strategies for each database were amended in 2007 and both sets of search strategies are detailed in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-30 10:07:50 +0000" MODIFIED_BY="[Empty name]">
<P>The bibliographies of each trial were searched for additional reports of RCTs. Authors of identified RCTs were contacted for additional data. In addition, companies who supplied the oxygen delivery devices and members of the International Respiratory Care Association were contacted for unpublished studies.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-11-04 18:55:56 +0000" MODIFIED_BY="Emma J Welsh">
<P>All studies that appeared potentially relevant were assessed by two reviewers, who independently selected the trials for inclusion in this review. Disagreement was resolved by consensus.</P>
<P>The selected trial was scored for blinding as double blind, single blind or not blinded/not known.</P>
<P>The quality of concealment of allocation was rated according to the method proposed by <LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>. Data for the trials was extracted by two reviewers (AC and JC).</P>
<SUBSECTION>
<HEADING LEVEL="6">Statistical considerations</HEADING>
<P>Subgroup analysis, determined in advance, was to include where possible:</P>
<OL>
<LI>A comparison of male with female patients</LI>
<LI>A comparison of oxygen therapy treatment versus no oxygen therapy</LI>
</OL>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-11-05 17:50:34 +0000" MODIFIED_BY="Emma J Welsh">
<STUDY_DESCRIPTION MODIFIED="2010-11-05 17:50:34 +0000" MODIFIED_BY="Emma J Welsh">
<P>The original literature search was conducted in 2000 and has been updated on an annual basis. A total of 758 references have been identified and screened for inclusion. One unpublished RCT (<LINK REF="STD-Braghiroli-2000" TYPE="STUDY">Braghiroli 2000</LINK>) was identified from the bibliographies of three review papers identified in the original search (<LINK REF="REF-Braghiroli-1993" TYPE="REFERENCE">Braghiroli 1993</LINK>; <LINK REF="REF-Donner-1990" TYPE="REFERENCE">Donner 1990</LINK>; <LINK REF="REF-Zielinski-2000" TYPE="REFERENCE">Zielinski 2000</LINK>). The latest search was in 2010.</P>
<P>Only one study was identified which met the inclusion criteria for this review (<LINK REF="STD-Braghiroli-2000" TYPE="STUDY">Braghiroli 2000</LINK>). This study has not yet been published. The controlled multi-centre study was commenced in 1988 and compared long-term oxygen therapy to a control, no oxygen therapy group. Patients of either gender and under 79 years of age with a diagnosis on X-ray examination of interstitial pulmonary fibrosis were considered for inclusion into the study. The patients were clinically stable and without other major causes of morbidity and mortality such as malignancy, unstable angina, or recent myocardial infarction, congestive cardiac failure, alcoholism, recent pulmonary embolism, diabetes or pregnancy. The included patients were hypoxic, arterial oxygen tension (PaO2) between 45-60 mm Hg (6.0-8.0 kPa). Total lung capacity (TLC) was &lt; 80% predicted. Pharmacological treatment was kept steady for as long as possible during the study. The patients were followed over a four year period. The outcome variables were survival, total lung capacity, dyspnoea trends and blood gases.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The method of randomisation for the study was not stated. The method of blinding was not described. However, random sampling was set up by blocks, each with six cases allocated to the treatment group and five cases to the control group. </P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-11-04 18:59:03 +0000" MODIFIED_BY="Emma J Welsh">
<P>Sixty two patients were randomized into the study, 37 to treatment with long-term domiciliary oxygen therapy (17 males and 20 females) and 25 (14 males and 11 females) to control group (no oxygen therapy). Forty nine of the patients (28 treated and 21 controls) had a diagnosis of idiopathic pulmonary fibrosis, and 13 (9 treated and 4 controls) had pulmonary fibrosis secondary to other diseases. Only mortality data with both disease groups combined was provided for the included patients (personal communication only). There was no difference in mortality at 12, 24 or 36 months between the treated and control groups. Mortality for both the oxygen treated and control groups was 91% after three years (Peto OR 0.99; 95% CI 0.16 to 6.26). The effect of oxygen therapy on physiological parameters was not indicated. Data on quality of life was not reported.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>There has been only one RCT of domiciliary long-term oxygen therapy in ILD. The results of this study have not been published due to difficulties in collecting data on quality of life from some of the participating centres (verbal communication). This study showed that home oxygen therapy did not improve survival in patients with ILD when respiratory insufficiency had developed, compared to no oxygen therapy.<BR/> <BR/>At the present time long-term oxygen therapy is prescribed if clinically indicated to treat hypoxaemia and relieve symptoms rather than on the basis of scientific evidence from RCTs. A non-randomized study of long term oxygen therapy in patients with idiopathic pulmonary fibrosis (<LINK REF="STD-Polonski-1995" TYPE="STUDY">Polonski 1995</LINK>) concluded that chronic home oxygen therapy attenuated cardiac dysfunction in the treated patients. However, the number of patients included in this study was small (n=18). The effect of long-term oxygen therapy on quality of life and physiological parameters in ILD remains unknown.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-04 19:00:02 +0000" MODIFIED_BY="Emma J Welsh">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-04 19:00:02 +0000" MODIFIED_BY="Emma J Welsh">
<P>The assumption that home oxygen therapy has a beneficial effect on survival in patients with ILD has not been demonstrated in this review. The only relevant trial showed that long-term oxygen therapy did not improve survival in patients with ILD. The effect of oxygen therapy on quality of life and physiological parameters was not reported.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Multicentre studies are required to assess the use of adjunctive measures such as oxygen therapy in ILD. However, randomized controlled trials are difficult to perform if a patient is hypoxic. Ethical concerns have been raised about the randomization of patients to placebo and this may be a bar to obtaining more appropriate health status data about the effects of oxygen in more severely hypoxaemic subjects with ILD. </P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We wish to acknowledge the assistance provided by the Cochrane Airways Review Group staff (Steve Milan, Toby Lasserson, Karen Blackhall and Liz Arnold) in identifying the trials from the register and obtaining copies of the papers and the three translators (Charlotta Pisinger, Anna Amstead and Derek Scoins) who translated the papers for us. </P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>AC and JC initiated the study. AC and JC reviewed the trials.<BR/>JC was responsible for data entry and analysis. All reviewers participated in the discussion and interpretation of the results. AC and JC wrote the paper. AC is guarantor for the study.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-11-05 11:33:23 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-10-28 08:38:40 +0000" MODIFIED_BY="Toby J Lasserson">
<INCLUDED_STUDIES MODIFIED="2009-10-28 08:38:40 +0000" MODIFIED_BY="Toby J Lasserson">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Braghiroli-2000" MODIFIED="2009-10-28 08:38:40 +0000" MODIFIED_BY="Toby J Lasserson" NAME="Braghiroli 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-10-28 08:38:40 +0000" MODIFIED_BY="Toby J Lasserson" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Braghiroli A, Donner CF</AU>
<TI>A multicentre randomized controlled trial on long term oxygen therapy in pulmonary fibrosis</TI>
<SO>Personal communication</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Polonski-1995" NAME="Polonski 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polonski L, Krzywiecki A, Polonska A, Tendera M, Cwiertka P, Oklek K, et al</AU>
<TI>Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. I. Effect on the course of the primary disease and on pulmonary circulation</TI>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>1995</YR>
<VL>94</VL>
<NO>4</NO>
<PG>331-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polonski L, Kusnierz B, Krzywiecki A, Polonska A, Tendera M, Oklek K, et al</AU>
<TI>Effects of long term oxygen therapy in patients with idiopathic pulmonary fibrosis. II. Effect of oxygen therapy on function of heart ventricles</TI>
<SO>Polskie Archiwum Medycyny Wewnetrznej</SO>
<YR>1995</YR>
<VL>94</VL>
<NO>4</NO>
<PG>337-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-11-05 11:33:23 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-11-05 11:33:23 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Braghiroli-1993" NAME="Braghiroli 1993" TYPE="JOURNAL_ARTICLE">
<AU>Braghiroli A, Ioli F, Spada EL, Vecchio C, Donner CF, Braghiroli A, et al</AU>
<TI>LTOT in pulmonary fibrosis</TI>
<SO>Monaldi Archives for Chest Disease</SO>
<YR>1993</YR>
<VL>48</VL>
<NO>5</NO>
<PG>437-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Crockett-1991" MODIFIED="2010-11-05 11:33:23 +0000" MODIFIED_BY="[Empty name]" NAME="Crockett 1991" TYPE="JOURNAL_ARTICLE">
<AU>Crockett AJ, Alpers JH, Moss JR</AU>
<TI>Home oxygen therapy: an audit of survival</TI>
<SO>Australian and New Zealand Journal of Medicine</SO>
<YR>1991</YR>
<VL>21</VL>
<NO>2</NO>
<PG>217-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donner-1990" NAME="Donner 1990" TYPE="JOURNAL_ARTICLE">
<AU>Donner CF, Braghiroli A, Ioli F, Zaccaria S</AU>
<TI>Long-term oxygen therapy in patients with diagnoses other than COPD</TI>
<SO>Lung</SO>
<YR>1990</YR>
<VL>168</VL>
<NO>Suppl</NO>
<PG>776-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reynolds-1998" NAME="Reynolds 1998" TYPE="JOURNAL_ARTICLE">
<AU>Reynolds HY</AU>
<TI>Diagnostic and management strategies for diffuse interstitial lung disease</TI>
<SO>Chest</SO>
<YR>1998</YR>
<VL>113</VL>
<PG>195-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zielinski-2000" NAME="Zielinski 2000" TYPE="JOURNAL_ARTICLE">
<AU>Zielinski J</AU>
<TI>Long-term oxygen therapy in conditions other than chronic obstructive pulmonary disease</TI>
<SO>Respiratory Care</SO>
<YR>2000</YR>
<VL>45</VL>
<NO>2</NO>
<PG>172-6</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Braghiroli-2000">
<CHAR_METHODS>
<P>Block randomization, with six cases allocated to the treatment group and five to the control group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Patients less than 79 years of age with interstitial pulmonary fibrosis. Inclusion criteria included a total lung capacity (TLC) &lt;80% predicted and an arterial oxygen tension (PaO2) of 45-60 mm Hg.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Long-term oxygen therapy versus a control group.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Survival over 4-years. Physiological parameters of total lung capacity, arterial blood gases and dyspnea. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Unpublished study - data from Donner CF.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Polonski-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>This study was not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-07-23 13:28:19 +0100" MODIFIED_BY="Toby J Lasserson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-07-23 13:28:19 +0100" MODIFIED_BY="Toby J Lasserson" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-07-23 13:28:19 +0100" MODIFIED_BY="Toby J Lasserson" RESULT="UNKNOWN" STUDY_ID="STD-Braghiroli-2000">
<DESCRIPTION>
<P>Block randomisation; concealment of randomisation not described. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-10-30 10:07:12 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Oxygen therapy versus no oxygen therapy</NAME>
<DICH_OUTCOME CHI2="2.564559530530518" CI_END="2.0718056119472448" CI_START="0.5013822160621241" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.0191989447443786" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="43" I2="22.013898441801057" I2_Q="22.013898441801057" ID="CMP-001.01" LOG_CI_END="0.3163490051180869" LOG_CI_START="-0.2998310744525119" LOG_EFFECT_SIZE="0.008258965332787532" METHOD="PETO" NO="1" P_CHI2="0.2774042824304169" P_Q="0.2774042824304169" P_Z="0.9580978448573962" Q="2.564559530530518" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="111" TOTAL_2="75" WEIGHT="300.0" Z="0.052540726772955286">
<NAME>Mortality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.60565969027527" CI_START="0.15304640722232588" DF="0" EFFECT_SIZE="0.49572214679025856" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.20565350464343102" LOG_CI_START="-0.8151768610475861" LOG_EFFECT_SIZE="-0.3047616782020775" NO="1" P_CHI2="1.0" P_Z="0.24189366178178107" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="25" WEIGHT="100.0" Z="1.170266742094257">
<NAME>Mortality at 12 months</NAME>
<DICH_DATA CI_END="1.60565969027527" CI_START="0.15304640722232588" EFFECT_SIZE="0.49572214679025856" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.20565350464343102" LOG_CI_START="-0.8151768610475861" LOG_EFFECT_SIZE="-0.3047616782020775" ORDER="1" O_E="-1.951612903225806" SE="0.5996408099987104" STUDY_ID="STD-Braghiroli-2000" TOTAL_1="37" TOTAL_2="25" VAR="2.781106600023883" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.864225400013791" CI_START="0.6386906520127237" DF="0" EFFECT_SIZE="1.7625933428535523" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.6870136912059094" LOG_CI_START="-0.19470944020494077" LOG_EFFECT_SIZE="0.24615212550048432" NO="2" P_CHI2="1.0" P_Z="0.2738090329855144" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="25" WEIGHT="100.0" Z="1.0943328659801923">
<NAME>Mortality at 24 months</NAME>
<DICH_DATA CI_END="4.864225400013791" CI_START="0.6386906520127237" EFFECT_SIZE="1.7625933428535523" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="12" LOG_CI_END="0.6870136912059094" LOG_CI_START="-0.19470944020494077" LOG_EFFECT_SIZE="0.24615212550048432" ORDER="2" O_E="2.112903225806452" SE="0.5179285319906253" STUDY_ID="STD-Braghiroli-2000" TOTAL_1="37" TOTAL_2="25" VAR="3.7278662936490345" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.259620669765086" CI_START="0.15523551578210246" DF="0" EFFECT_SIZE="0.9857562798538454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.7965480159549412" LOG_CI_START="-0.8090089110184446" LOG_EFFECT_SIZE="-0.006230447531751721" NO="3" P_CHI2="1.0" P_Z="0.9878634588036053" STUDIES="1" TAU2="0.0" TOTAL_1="37" TOTAL_2="25" WEIGHT="100.0" Z="0.015211485266759776">
<NAME>Mortality at 3 years</NAME>
<DICH_DATA CI_END="6.259620669765084" CI_START="0.15523551578210248" EFFECT_SIZE="0.9857562798538454" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="23" LOG_CI_END="0.7965480159549411" LOG_CI_START="-0.8090089110184446" LOG_EFFECT_SIZE="-0.006230447531751721" ORDER="3" O_E="-0.016129032258064058" SE="0.943112086539133" STUDY_ID="STD-Braghiroli-2000" TOTAL_1="37" TOTAL_2="25" VAR="1.1242771361798674" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-05 11:58:52 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-05 11:32:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-30 10:05:03 +0000" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-05 11:32:54 +0000" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="5">
<TR>
<TH>
<P>Database searched</P>
</TH>
<TH>
<P>Search (up to 2006)</P>
</TH>
<TH>
<P>Search (from 2007 onwards)</P>
</TH>
</TR>
<TR>
<TD>
<P>CENTRAL</P>
</TD>
<TD>
<P>#1. LUNG DISEASES INTERSTITIAL explode tree 1 (MeSH);<BR/>#2. (interstitial* near lung* near disease*);<BR/>#3. alveolitis*;<BR/>#4. (interstitial near pneumo*);<BR/>#5. (lung* near purpura);<BR/>#6. (goodpasture* near syndrome*);<BR/>#7. granulomatosis;<BR/>#8. bagassosis;<BR/>#9. (berylliosis or beryllium);<BR/>#10. hemosiderosis;<BR/>#11. (hamman-rich next syndrome*);<BR/>#12. (pulmonary near fibros*);<BR/>#13. (histiocytosis near langerhans);<BR/>#14. (pulmonary near sarcoidosis);<BR/>#15. (wegener* near granuloma*);<BR/>#16. ((bird* near lung*) or (bird* near disease*));<BR/>#17. ((pigeon* near lung*) or (pigeon* near disease*));<BR/>#18. ((farmer* near lung*) or (farmer* near disease*));<BR/>#19. (asbestosis or byssinosis or silicosis or anthracosis or anthracosilicosis);<BR/>#20. pneumoconiosis;<BR/>#21. (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20) 949;<BR/>#22. OXYGEN INHALATION THERAPY explode tree 1 (MeSH);<BR/>#23. OXYGEN single term (MeSH);<BR/>#24. HOME CARE SERVICES explode tree 1 (MeSH);<BR/>#25. ((oxygen next therap*) or ((home* or domicil*) and oxygen) or (long next term next oxygen next therapy) or ltot);<BR/>#26. (#22 or #23 or #24 or #25); #27 (#26 and #21)</P>
</TD>
<TD>
<P>#1 MeSH descriptor Lung Diseases, Interstitial explode all trees<BR/>#2 pulmonary near fibros*<BR/>#3 interstitial* near lung*<BR/>#4 (#1 OR #2 OR #3)<BR/>#5 MeSH descriptor Oxygen Inhalation Therapy explode all trees<BR/>#6 MeSH descriptor Home Care Services explode all trees<BR/>#7 MeSH descriptor Oxygen, this term only<BR/>#8 ((oxygen next therap*) or ((home* or domicil*) and oxygen) or (long next term next oxygen next therapy) or ltot)<BR/>#9 (#5 OR #6 OR #7 OR #8)<BR/>#10 (#4 AND #9)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
<P>(combined with an RCT filter as described in the <A HREF="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002872/frame.html">Airways Group Module</A>)</P>
</TD>
<TD>
<P>1. exp Lung Diseases, Interstitial/<BR/>2. alveolitis.mp.<BR/>3. (interstitial adj3 lung$ adj3 disease$).mp.<BR/>4. (interstitial adj3 (pneumonia or pneumonitis)).mp.<BR/>5. (lung adj3 purpura).mp.<BR/>6. (goodpasture$ adj3 syndrome$).mp.<BR/>7. granulomatosis.mp.<BR/>8. bagassosis.mp.<BR/>9. (beryllium adj3 disease).mp.<BR/>10. hemosiderosis.mp.<BR/>11. hamman-rich syndrome.mp.<BR/>12. (pulmonary adj3 (fibrosis or fibroses)).mp.<BR/>13. histiocytosis langerhans-cell.mp.<BR/>14. pneumoconiosis.mp.<BR/>15. (asbestosis or berylliosis or byssinosis or siderosis or silicosis or anthracosis or anthracosilicosis or silicotuberculosis).mp.<BR/>16. (pulmonary adj3 sarcoidosis).mp.<BR/>17. (wegener$ adj3 granuloma$).mp.<BR/>18. ((bird$ or pigeon$ or hen$ or farmer$) adj3 (lung$ or disease$)).mp.<BR/>19. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18<BR/>20. exp OXYGEN INHALATION THERAPY/<BR/>21. exp OXYGEN/<BR/>22. exp HOME CARE SERVICES/<BR/>23. ((oxygen adj3 therap$) or ((home$ or domicil$) adj5 oxygen) or long term oxygen therap$ or LTOT).mp.<BR/>24. 20 or 21 or 22 or 23<BR/>25. 19 and 24<BR/>
</P>
</TD>
<TD>
<P>1. exp Lung Diseases, Interstitial/<BR/>2. (interstitial adj3 lung$ adj3 disease$).mp.<BR/>3. (interstitial adj3 (pneumonia or pneumonitis)).mp.<BR/>4. (pulmonary adj3 (fibrosis or fibroses)).mp.<BR/>5. exp OXYGEN INHALATION THERAPY/<BR/>6. exp OXYGEN/<BR/>7. exp HOME CARE SERVICES/<BR/>8. ((oxygen adj3 therap$) or ((home$ or domicil$) adj5 oxygen) or long term oxygen therap$ or LTOT).mp.<BR/>9. 5 or 6 or 7 or 8<BR/>10. or/1-4<BR/>11. 9 and 10<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE</P>
<P>(combined with an RCT filter as described in the <A HREF="http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002872/frame.html">Airways Group Module</A>)</P>
</TD>
<TD>
<P>1. exp Interstitial Lung Disease/<BR/>2. (interstitial adj3 (lung$ or disease$ or fibros$ or pneumonitis or pneumonia or pneumopathy)).mp.<BR/>3. (Berylliosis or Beryllium).mp.<BR/>4. (Alveolitis or Pulmonary Fibrosis).mp.<BR/>5. (Hamman Rich adj3 (Disease$ or Syndrome$)).mp.<BR/>6. (Fibroid adj3 Phthisis).mp.<BR/>7. (Caplan$ adj3 (Syndrome$ or Disease$)).mp.<BR/>8. (Pneumoconiosis or Pneumokoniosis or Pneumonoconiosis or Pneumonokoniosis).mp.<BR/>9. (Lung adj3 Coniosis).mp.<BR/>10. ((Wegener$ or Pneumogenic or respiratory) adj3 (granulomatosis or disease$ or syndrome$)).mp.<BR/>11. (lung$ adj3 (coniosis or alveolitis or emphysema$ or fibrosis or infec$ or occupational)).mp.<BR/>12. (lung adj3 purpura).mp.<BR/>13. (pulmonary adj3 (fibrosis or fibroses)).mp.<BR/>14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13;<BR/>15. exp Oxygen Therapy/<BR/>16. exp OXYGEN/<BR/>17. exp Home Care/<BR/>18. ((oxygen adj3 therap$) or ((home$ or domicil$) adj5 oxygen) or long term oxygen therap$ or LTOT).mp.<BR/>19. 15 or 16 or 17 or 18<BR/>20. 14 and 19<BR/>
</P>
</TD>
<TD>
<P>1. exp Interstitial Lung Disease/<BR/>2. (interstitial adj3 (lung$ or disease$ or fibros$ or pneumonitis or pneumonia or pneumopathy)).mp.<BR/>3. (pulmonary adj3 (fibrosis or fibroses)).mp.<BR/>4. exp Oxygen Therapy/<BR/>5. exp OXYGEN/<BR/>6. exp Home Care/<BR/>7. ((oxygen adj3 therap$) or ((home$ or domicil$) adj5 oxygen) or long term oxygen therap$ or LTOT).mp.<BR/>8. 4 or 5 or 6 or 7<BR/>9. or/1-3<BR/>10. 8 and 9<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Airways Group Specialised Register (restricted to records coded as 'interstitial lung disease)</P>
</TD>
<TD>
<P>(home OR domiciliary) AND oxygen</P>
</TD>
<TD>
<P>oxygen* or home* or domicil* or LTOT</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>